Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

55.63 +0.36 (+0.66%)
Streaming Delayed Price Updated: 3:15 PM EST, Feb 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 627,488
Open 55.15
Bid (Size) 55.59 (3)
Ask (Size) 55.68 (4)
Prev. Close 55.27
Today's Range 54.42 - 56.52
52wk Range 38.94 - 86.95
Shares Outstanding 78,294,139
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Ready to Buy the Dip? Consider This Gene Editing Stock
CRISPR Therapeutics shares had a rough 2022, but the stock might soon surge back. 
Via The Motley Fool
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%
Cathie Wood is bullish about these stocks. And so are Wall Street analysts. 
Via The Motley Fool

Performance

YTD
+35.70%
+35.70%
1 Month
+17.85%
+17.85%
3 Month
+11.94%
+11.94%
6 Month
-31.64%
-31.64%
1 Year
-10.78%
-10.78%

More News

Read More
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
Via Talk Markets
3 No-Brainer Growth Stocks to Buy in 2023
Via The Motley Fool
Why Editas Medicine's Shares Jumped This Week
Via The Motley Fool
5 Reasons to Buy Vertex Pharmaceuticals Now
Via The Motley Fool
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Via The Motley Fool
Is Editas Medicine Stock a Buy Now?
Via The Motley Fool
3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later
Via InvestorPlace
Michael Burry vs. Jim Cramer: Is It Time to Buy or Sell Stocks Now?
Via InvestorPlace
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
Via Benzinga
Jim Cramer Says This Is 'One Of Those Crazy Science Stocks That In This Market Will Work Perfectly'
Via Benzinga
3 Things About CRISPR Therapeutics That Smart Investors Know
Via The Motley Fool
7 CRISPR Stocks With the Best Long-Term Potential
Via InvestorPlace
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
Via The Motley Fool
3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later
Via InvestorPlace
3 Gene Editing Stocks With the Best Long-Term Potential
Via InvestorPlace
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?
Via The Motley Fool
3 Smart Stocks to Buy if a Recession Is on the Way
Via The Motley Fool
CRISPR Therapeutics Stock: Bull vs. Bear
Via The Motley Fool
7 Biotech Stocks That Will Make You Rich in 10 Years
Via InvestorPlace
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
Via InvestorPlace
2 Stocks Down More Than 25% to Buy Right Now
Via The Motley Fool
5 Potentially Explosive Stocks to Buy in 2023
Via The Motley Fool
More Likely to 5X First: CRISPR Therapeutics vs. InMode
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.